What is the share price of Alkem Laboratories Ltd (ALKEM) today?
The share price of ALKEM as on 26th June 2025 is ₹4841. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.What is the return on Alkem Laboratories Ltd (ALKEM) share?
The past returns of Alkem Laboratories Ltd (ALKEM) share are- Past 1 week: 0.74%
- Past 1 month: -8.66%
- Past 3 months: -3.24%
- Past 6 months: -10.49%
- Past 1 year: -2.67%
- Past 3 years: 61.08%
- Past 5 years: 106.06%
What are the peers or stocks similar to Alkem Laboratories Ltd (ALKEM)?
The peers or stocks similar to Alkem Laboratories Ltd (ALKEM) include:What is the dividend yield % of Alkem Laboratories Ltd (ALKEM) share?
The current dividend yield of Alkem Laboratories Ltd (ALKEM) is 0.93.What is the market cap of Alkem Laboratories Ltd (ALKEM) share?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Alkem Laboratories Ltd (ALKEM) is ₹57881.42 Cr as of 26th June 2025.What is the 52 week high and low of Alkem Laboratories Ltd (ALKEM) share?
The 52-week high of Alkem Laboratories Ltd (ALKEM) is ₹6439.90 and the 52-week low is ₹4491.65.What is the PE and PB ratio of Alkem Laboratories Ltd (ALKEM) stock?
The P/E (price-to-earnings) ratio of Alkem Laboratories Ltd (ALKEM) is 26.73. The P/B (price-to-book) ratio is 5.40.Which sector does Alkem Laboratories Ltd (ALKEM) belong to?
Alkem Laboratories Ltd (ALKEM) belongs to the Health Care sector & Pharmaceuticals sub-sector.How to buy Alkem Laboratories Ltd (ALKEM) shares?
You can directly buy Alkem Laboratories Ltd (ALKEM) shares on Tickertape. Simply sign up, connect your demat account and place your order.
Alkem Laboratories Ltd
ALKEM Share Price
4,841.000.27% (-13.00)
High
—
—
Low
—
—
Returns
—
—
1D
1W
1M
1Y
5Y
Max
SIP
1D
1W
1M
1Y
5Y
Max
SIP
ALKEM Stock Scorecard
Performance
LowHasn't fared well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
HighShowing good signs of profitability & efficiency
Entry point
GoodThe stock is underpriced and is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
ALKEM Performance & Key Metrics
ALKEM Performance & Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| 26.73 | 5.40 | 0.93% |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 36.01 | 6.54 | 0.84% |
45%
Analysts have suggested that investors can buy this stock
from 20 analysts
Price Upside
Earnings Growth
Rev. Growth
ALKEM Company Profile
Alkem Laboratories Limited is engaged in the development, manufacture and sale of pharmaceutical and neutraceutical products.
SUNPHARMA
PE Ratio
36.66
36.66
1Y Return
9.77%
9.77%
Buy Reco %
87.88
87.88
CIPLA
PE Ratio
23.19
23.19
1Y Return
2.35%
2.35%
Buy Reco %
74.19
74.19
DRREDDY
PE Ratio
19.45
19.45
1Y Return
8.85%
8.85%
Buy Reco %
55.17
55.17
TORNTPHARM
PE Ratio
57.07
57.07
1Y Return
15.48%
15.48%
Buy Reco %
72.00
72.00
ZYDUSLIFE
PE Ratio
21.83
21.83
1Y Return
7.87%
7.87%
Buy Reco %
46.43
46.43
ALKEM Sentiment Analysis
ALKEM Sentiment Analysis
New
Crisp summary & key insights to decode earnings calls instantly
ALKEM Stock Summary · June 2025
In Q4 FY2025, the company reported a revenue increase of 7.1% to Rs. 31,438 million, driven by strong domestic sales, particularly in anti-diabetes and respiratory segments, despite challenges in the injectable anti-infective portfolio. While the domestic market faces growth constraints due to price controls, optimism remains for mid-single-digit growth in the U.S. market, supported by strategic R&D investments and new product launches. The company is also focusing on expanding its presence in international markets and enhancing its portfolio through targeted acquisitions. However, operating losses from new initiatives in the CDMO and MedTech sectors pose short-term challenges, alongside anticipated tax rate increases that may impact profitability. Overall, a commitment to innovation and operational excellence underpins the company's strategy for sustainable growth.
ALKEM Stock Growth Drivers
ALKEM Stock Growth Drivers
7Strong Financial Performance
Alkem Laboratories reported a total revenue from operations of Rs. 31,438 million for Q4 FY'25,
Market Outperformance
For FY'25, Alkem Laboratories achieved a volume growth of 2.1%, surpassing the Indian Pharmaceutical Market's
ALKEM Stock Challenges
ALKEM Stock Challenges
5Decline in Gross Margins
The company has experienced a decline in gross margins for Q4, attributed to several factors:
Operating Losses from New Initiatives
The company anticipates significant operating losses from new business initiatives, specifically the CDMO and MedTech
ALKEM Forecast
ALKEM Forecasts
Price
Revenue
Earnings
ALKEM Share Price Forecast
ALKEM Share Price Forecast
2025
Current
₹4,841.00
Baseline
Forecast for Jun 2026
High
₹—
Median
₹—
Low
₹—
All values in ₹
2025
Current
₹4,841.00
Baseline
Forecast for Jun 2026
High
₹—
Median
₹—
Low
₹—
All values in ₹
ALKEM Company Revenue Forecast
ALKEM Company Revenue Forecast
2025
Current
₹13.46
Baseline
Forecast for Mar 2026
High
₹—
Median
₹—
Low
₹—
All values in ₹ Thousand cr.
2025
Current
₹13.46
Baseline
Forecast for Mar 2026
High
₹—
Median
₹—
Low
₹—
All values in ₹ Thousand cr.
ALKEM Stock EPS (Earnings Per Share) Forecast
ALKEM Stock EPS (Earnings Per Share) Forecast
2025
Current
₹181.11
Baseline
Forecast for Mar 2026
High
₹—
Median
₹—
Low
₹—
All values in ₹
2025
Current
₹181.11
Baseline
Forecast for Mar 2026
High
₹—
Median
₹—
Low
₹—
All values in ₹
ALKEM
ALKEM
Income
Balance Sheet
Cash Flow
Annual Normal View
ALKEM Income Statement
ALKEM Income Statement
Annual Normal View
| Financial Year | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 5,799.54 | 6,516.59 | 7,444.89 | 8,448.58 | 9,098.22 | 10,796.84 | 11,815.34 | 12,978.42 | 13,458.26 | 13,458.26 | ||||||||||
Raw Materials | 2,511.13 | 2,477.74 | 2,941.33 | 3,574.89 | 3,832.30 | 4,715.77 | 4,444.47 | 4,923.46 | 10,452.37 | 10,452.37 | ||||||||||
| Power & Fuel Cost | 86.34 | 112.64 | 121.48 | 130.14 | 129.95 | 162.96 | 163.94 | 162.58 | ||||||||||||
| Employee Cost | 1,003.85 | 1,191.64 | 1,362.46 | 1,505.49 | 1,621.03 | 1,962.71 | 2,131.35 | 2,201.01 | ||||||||||||
| Selling & Administrative Expenses | 1,014.86 | 1,175.61 | 1,288.44 | 1,412.40 | 1,224.58 | 1,722.20 | 2,163.71 | 2,163.46 | ||||||||||||
| Operating & Other expenses | 72.40 | 434.62 | 528.71 | 248.05 | 114.76 | 32.59 | 1,189.32 | 1,093.07 | ||||||||||||
EBITDA | 1,110.96 | 1,124.34 | 1,202.47 | 1,577.61 | 2,175.60 | 2,200.61 | 1,722.55 | 2,434.84 | 3,005.89 | 3,005.89 | ||||||||||
| Depreciation/Amortization | 101.17 | 143.03 | 193.18 | 252.76 | 274.58 | 303.96 | 310.42 | 299.30 | 357.16 | 357.16 | ||||||||||
| PBIT | 1,009.79 | 981.31 | 1,009.29 | 1,324.85 | 1,901.02 | 1,896.65 | 1,412.13 | 2,135.54 | 2,648.73 | 2,648.73 | ||||||||||
| Interest & Other Items | 45.16 | 55.33 | 54.63 | 65.06 | 58.92 | 52.37 | 107.36 | 112.41 | 121.70 | 121.70 | ||||||||||
| PBT | 964.63 | 925.98 | 954.66 | 1,259.79 | 1,842.10 | 1,844.28 | 1,304.77 | 2,023.13 | 2,527.03 | 2,527.03 | ||||||||||
| Taxes & Other Items | 72.60 | 295.04 | 194.15 | 132.72 | 257.08 | 198.66 | 320.60 | 227.36 | 361.55 | 361.55 | ||||||||||
| Net Income | 892.03 | 630.94 | 760.51 | 1,127.07 | 1,585.02 | 1,645.62 | 984.17 | 1,795.77 | 2,165.48 | 2,165.48 | ||||||||||
| EPS | 74.61 | 52.77 | 63.61 | 94.26 | 132.57 | 137.63 | 82.31 | 150.19 | 181.11 | 181.11 | ||||||||||
| DPS | 15.00 | 13.00 | 16.00 | 25.00 | 30.00 | 34.00 | 50.00 | 40.00 | 45.00 | 42.00 | ||||||||||
| Payout ratio | 0.20 | 0.25 | 0.25 | 0.27 | 0.23 | 0.25 | 0.61 | 0.27 | 0.25 | 0.23 |
ALKEM Company Updates
FY 2025FY 2025
Investor Presentation
May 29PDF
Mar 19PDF
Feb 7PDF
Nov 13PDF
FY 2023FY 2023
Investor Presentation
May 19PDF
Feb 10PDF
Nov 11PDF
Aug 5PDF
ALKEM Stock Peers
ALKEM Past Performance & Peer Comparison
ALKEM Past Performance & Peer Comparison
Comparing 3 stocks from
Health CarePharmaceuticals
Compare valuation on Screener
Health CarePharmaceuticals
Valuation
Technical
Forecast
Compare valuation on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Alkem Laboratories Ltd | 26.73 | 5.40 | 0.93% |
| Sun Pharmaceutical Industries Ltd | 36.66 | 5.97 | 0.96% |
| Cipla Ltd | 23.19 | 3.91 | 1.06% |
| Dr Reddy's Laboratories Ltd | 19.45 | 3.89 | 0.61% |
ALKEM Stock Price Comparison
Compare ALKEM with any stock or ETFCompare ALKEM with any stock or ETF
ALKEM
ALKEM Holdings
ALKEM Shareholdings
ALKEM Promoter Holdings Trend
ALKEM Promoter Holdings Trend
Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better
Pledged promoter holdings is insignificant
ALKEM Institutional Holdings Trend
ALKEM Institutional Holdings Trend
Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.
In last 3 months, retail holding in the company has almost stayed constant
Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock
In last 3 months, foreign institutional holding of the company has almost stayed constant
ALKEM Shareholding Pattern
ALKEM Shareholding Pattern
ALKEM Shareholding History
ALKEM Shareholding History
Foreign Institutions
Mutual Funds Invested in ALKEM
Mutual Funds Invested in ALKEM
Mutual Fund Holding
Increasing Mutual Fund holdings are generally considered good, as it reflects that fund managers are becoming more bullish about the stock
In last 3 months, mutual fund holding of the company has almost stayed constant
Top 5 Mutual Funds holding Alkem Laboratories Ltd
| Funds (Top 5) | The rupee value of the stock held by the fund divided by the stock’s market cap Market-cap held | Percentage of the fund’s portfolio invested in the stock Weight | Change in the portfolio weight of the stock over the last 3 months 3M holding change | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months Portfolio rank(3M change) |
|---|---|---|---|---|
The rupee value of the stock held by the fund divided by the stock’s market cap 1.2973% | Percentage of the fund’s portfolio invested in the stock 2.41% | Change in the portfolio weight of the stock over the last 3 months -0.10% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 11/88 (-1) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 1.0648% | Percentage of the fund’s portfolio invested in the stock 1.04% | Change in the portfolio weight of the stock over the last 3 months 0.06% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 20/231 (-1) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 1.0335% | Percentage of the fund’s portfolio invested in the stock 2.77% | Change in the portfolio weight of the stock over the last 3 months 0.07% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 7/109 (-1) |
Compare 3-month MF holding change on Screener
smallcases containing ALKEM stock
smallcases containing ALKEM stock
Looks like this stock is not in any smallcase yet.
ALKEM Events
ALKEM Events
ALKEM Dividend Trend
No Trend In Dividends
Dividends are the portion of earnings that a company distributes to all its shareholders every year
ALKEM has shown inconsistent dividend trend over the last 5 years
Dividend Yield
Dividend return is one of the most important things to be considered while investing for long term. It is the additional return on top of what investors earn through price appreciation
Current dividend yield is 0.93%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹9.27 every year
Dividends
Corp. Actions
Announcements
Legal Orders
Dividends
ALKEM Dividend Trend
No Trend In Dividends
Dividends are the portion of earnings that a company distributes to all its shareholders every year
ALKEM has shown inconsistent dividend trend over the last 5 years
Dividend Yield
Dividend return is one of the most important things to be considered while investing for long term. It is the additional return on top of what investors earn through price appreciation
Current dividend yield is 0.93%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹9.27 every year
ALKEM Upcoming Dividends
ALKEM Upcoming Dividends
No upcoming dividends are available
ALKEM Past Dividends
ALKEM Past Dividends
Cash Dividend
Ex DateEx DateFeb 14, 2025
Interim
Interim | Div/Share: ₹37.00
Dividend/Share
₹37.00
Ex DateEx Date
Feb 14, 2025
Cash Dividend
Ex DateEx DateAug 9, 2024
Final
Final | Div/Share: ₹5.00
Dividend/Share
₹5.00
Ex DateEx Date
Aug 9, 2024
Cash Dividend
Ex DateEx DateFeb 16, 2024
Interim
Interim | Div/Share: ₹35.00
Dividend/Share
₹35.00
Ex DateEx Date
Feb 16, 2024
Cash Dividend
Ex DateEx DateAug 10, 2023
Final
Final | Div/Share: ₹10.00
Dividend/Share
₹10.00
Ex DateEx Date
Aug 10, 2023
Cash Dividend
Ex DateEx DateFeb 17, 2023
Interim
Interim | Div/Share: ₹15.00
Dividend/Share
₹15.00
Ex DateEx Date
Feb 17, 2023
ALKEM Stock News & Opinions
ALKEM Stock News & Opinions
Articles & Videos
Spotlight
Alkem Laboratories Ltd up for third straight session
Alkem Laboratories Ltd is up for a third straight session today. The stock is quoting at Rs 4975, up 2.08% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is up around 0.12% on the day, quoting at 25133.1. The Sensex is at 82476.63, up 0.04%. Alkem Laboratories Ltd has slipped around 0.91% in last one month. Meanwhile, Nifty Pharma index of which Alkem Laboratories Ltd is a constituent, has slipped around 3.86% in last one month and is currently quoting at 21826.8, up 0.42% on the day. The volume in the stock stood at 1.76 lakh shares today, compared to the daily average of 1.93 lakh shares in last one month. The benchmark June futures contract for the stock is quoting at Rs 4995.5, up 2.03% on the day. Alkem Laboratories Ltd is down 1.81% in last one year as compared to a 8.03% jump in NIFTY and a 11.32% jump in the Nifty Pharma index.The PE of the stock is 27.89 based on TTM earnings ending March 25.Powered by Capital Market - Live
2 weeks agoCapital Market - Live
Spotlight
Volumes spurt at Alkem Laboratories Ltd counter
Tata Technologies Ltd, Aditya Birla Fashion & Retail Ltd, Kaynes Technology India Ltd, Sun Pharma Advanced Research Company Ltd are among the other stocks to see a surge in volumes on BSE today, 04 June 2025.Alkem Laboratories Ltd notched up volume of 18.24 lakh shares by 10:46 IST on BSE, a 446.04 fold spurt over two-week average daily volume of 4088 shares. The stock slipped 1.42% to Rs.4,922.05. Volumes stood at 8367 shares in the last session.Tata Technologies Ltd witnessed volume of 99.99 lakh shares by 10:46 IST on BSE, a 72.75 times surge over two-week average daily volume of 1.37 lakh shares. The stock dropped 1.56% to Rs.755.50. Volumes stood at 1.37 lakh shares in the last session.Aditya Birla Fashion & Retail Ltd registered volume of 397.49 lakh shares by 10:46 IST on BSE, a 47.36 fold spurt over two-week average daily volume of 8.39 lakh shares. The stock slipped 9.35% to Rs.77.94. Volumes stood at 3.75 lakh shares in the last session.Kaynes Technology India Ltd witnessed volume of 5.69 lakh shares by 10:46 IST on BSE, a 39.6 times surge over two-week average daily volume of 14375 shares. The stock dropped 0.79% to Rs.5,740.05. Volumes stood at 10611 shares in the last session.Sun Pharma Advanced Research Company Ltd registered volume of 7 lakh shares by 10:46 IST on BSE, a 4.54 fold spurt over two-week average daily volume of 1.54 lakh shares. The stock slipped 17.00% to Rs.162.35. Volumes stood at 73862 shares in the last session.Powered by Capital Market - Live
3 weeks agoCapital Market - Live
Earnings
Alkem Laboratories consolidated net profit rises 4.19% in the March 2025 quarter
Net profit of Alkem Laboratories rose 4.19% to Rs 305.86 crore in the quarter ended March 2025 as against Rs 293.56 crore during the previous quarter ended March 2024. Sales rose 7.08% to Rs 3143.75 crore in the quarter ended March 2025 as against Rs 2935.82 crore during the previous quarter ended March 2024. For the full year,net profit rose 20.59% to Rs 2165.48 crore in the year ended March 2025 as against Rs 1795.77 crore during the previous year ended March 2024. Sales rose 2.34% to Rs 12964.52 crore in the year ended March 2025 as against Rs 12667.58 crore during the previous year ended March 2024. ParticularsQuarter EndedYear EndedMar. 2025Mar. 2024% Var.Mar. 2025Mar. 2024% Var. Sales3143.752935.82 7 12964.5212667.58 2 OPM %12.4513.69 -19.3817.73 - PBDT508.83463.29 10 2884.192443.92 18 PBT396.34379.86 4 2527.032144.62 18 NP305.86293.56 4 2165.481795.77 21 Powered by Capital Market - Live
3 weeks agoCapital Market - Live
Corporate
Alkem Laboratories to conduct AGM
Alkem Laboratories announced that the 51th Annual General Meeting(AGM) of the company will be held on 25 August 2025.Powered by Capital Market - Live
4 weeks agoCapital Market - Live
Earnings
Alkem Laboratories standalone net profit declines 14.78% in the March 2025 quarter
Net profit of Alkem Laboratories declined 14.78% to Rs 276.94 crore in the quarter ended March 2025 as against Rs 324.97 crore during the previous quarter ended March 2024. Sales declined 13.55% to Rs 2044.94 crore in the quarter ended March 2025 as against Rs 2365.37 crore during the previous quarter ended March 2024. For the full year,net profit rose 30.55% to Rs 2280.89 crore in the year ended March 2025 as against Rs 1747.15 crore during the previous year ended March 2024. Sales rose 10.67% to Rs 8813.44 crore in the year ended March 2025 as against Rs 7963.85 crore during the previous year ended March 2024. ParticularsQuarter EndedYear EndedMar. 2025Mar. 2024% Var.Mar. 2025Mar. 2024% Var. Sales2044.942365.37 -14 8813.447963.85 11 OPM %14.5117.23 -24.4620.98 - PBDT391.47470.63 -17 2587.151897.10 36 PBT299.83401.53 -25 2303.541657.96 39 NP276.94324.97 -15 2280.891747.15 31 Powered by Capital Market - Live
4 weeks agoCapital Market - Live
Corporate
Board of Alkem Laboratories recommends final dividend
Alkem Laboratories announced that the Board of Directors of the Company at its meeting held on 29 May 2025, inter alia, have recommended the final dividend of Rs 8 per equity Share (i.e. 400%) , subject to the approval of the shareholders.Powered by Capital Market - Live
4 weeks agoCapital Market - Live
Corporate
Alkem Laboratories to discuss results
Alkem Laboratories will hold a meeting of the Board of Directors of the Company on 29 May 2025.Powered by Capital Market - Live
1 month agoCapital Market - Live
Spotlight
Alkem Labs' subsidiary concludes acquisition of 100% stake in Bombay Ortho
In February this year, Alkem Medtech had executed a binding offer outlining the terms and conditions with respect to the acquisition of 100% stake of Bombay Ortho Industries. Bombay Ortho is a manufacturer and supplier of the orthopedic implants such as hip and knee implants, which are extensively used in the orthopedic field. It had recorded turnover of Rs 5.5 crore in the year ended on 31 March 2024. The cost of this acquisition was Rs 147 crore, payable in four tranches, subject to adjustment on debt, debt like items and change in normalized working capital as on closing date. In March 2025, Alkem Medtech and Bombay Ortho had executed a share purchase and share subscription agreement in this regard. In an exchange filing made post market hours on Wednesday, Alkem Labs stated that the acquisition of 100% stake in Bombay Ortho has been completed. The proposed investment by our wholly owned subsidiary 'Alkem MedTech Private Limited' is a strategic investment which will help to gain manufacturing capabilities to participate in growing orthopedic space and leveraging Bombay Ortho's expertise within the hip and knee implants segment,' Alkem Laboratories had said in a statement. Alkem Laboratories is engaged in the pharmaceutical business with global operations. The company is engaged in the development, manufacture, and sale of pharmaceutical and nutraceutical products. The company's consolidated net profit declined 1.8% to Rs 625.82 crore in Q3 FY25 as compared with Rs 637.37 crore in Q3 FY24. Net sales rose 1.5% YoY to Rs 3,374.28 crore in Q3 FY25. The scrip shed 0.08% to currently trade at Rs 4952.50 on the BSE. Powered by Capital Market - Live
2 months agoCapital Market - Live
Corporate
Alkem MedTech acquires Bombay Ortho Industries
Alkem Laboratories announced that its wholly owned subsidiary, Alkem MedTech has completed the acquisition of Bombay Ortho Industries. Accordingly, Bombay Ortho Industries has become a step-down subsidiary of the company. Powered by Capital Market - Live
2 months agoCapital Market - Live
Spotlight
Alkem Lab gains as Bioequivalence Center clears USFDA inspection without observations
The inspection, conducted from March 10 to March 13, 2025, concluded that no Form 483 had been issued. Alkem Laboratories is engaged in the pharmaceutical business with global operations. The company is engaged in the development, manufacture, and sale of pharmaceutical and nutraceutical products. The company's consolidated net profit declined 1.8% to Rs 625.82 crore in Q3 FY25 as compared with Rs 637.37 crore in Q3 FY24. Net sales rose 1.5% YoY to Rs 3,374.28 crore in Q3 FY25.Powered by Capital Market - Live
3 months agoCapital Market - Live
Over the last 5 years, revenue has grown at a yearly rate of 11.76%, vs industry avg of 9.02%
Over the last 5 years, market share increased from 3.39% to 3.41%
Over the last 5 years, net income has grown at a yearly rate of 18.75%, vs industry avg of 15.29%